EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
about
Role of microRNA-26b in glioma development and its mediated regulation on EphA2Emerging therapeutic biomarkers in endometrial cancerAntagonism of tumoral prolactin receptor promotes autophagy-related cell death.Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cellsLack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancerImmunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.EphA2 is a critical oncogene in melanoma.Therapeutic advances in women's cancersPrognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.Personalized therapy in endometrial cancer: challenges and opportunities.Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical studyTherapeutic synergy between microRNA and siRNA in ovarian cancer treatment.Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain.Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinomaRoles of EphA2 in Development and Disease.EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.Emerging therapeutic targets in endometrial cancer.The Eph/Ephrin family in cancer metastasis: communication at the service of invasion.Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer.Endometrial Carcinoma: Specific Targeted Pathways.Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck.Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer.Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer.Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients.Prognostic role of EphA2 in various human carcinomas: a meta-analysis of 23 related studies.
P2860
Q21135751-02D12D52-7155-43DF-B319-CE2B925264A8Q26865904-9295EA84-ED60-4164-9466-3C01942DF01FQ30579272-A11F5DAC-364C-4E1A-A85D-AEC9630DB777Q33599430-CA7DB5CB-0E40-4709-8144-9276B0C452F2Q33778507-E5BF2425-DFE3-45F9-8F47-45D6EBF6794AQ33904883-66CEEBAA-BCC1-438E-8F18-F744499D66F2Q34257256-BFBD0184-B785-4EE0-B489-594840D93118Q34616549-E5294E52-9EF5-48DC-AB41-174134261373Q34979610-49983559-72A4-49D7-967F-43EEF1BF0EB9Q35163679-0D9FC01D-8F48-4C2F-B963-99B7421C3928Q35218960-722DBED3-DAA7-43CB-AD8C-14ED97EBEF37Q35418973-E6E31A0A-1453-482D-A50B-D7594A268E81Q35879733-23268497-D96D-4459-963E-C1FCABA4C536Q35911350-7699DDDA-45C5-4516-9437-975D997F3100Q36405508-1C0D2F5E-AE0E-47FB-AC0A-8AF1165476CFQ36576644-0729DD2B-F9C3-4218-A4BB-8D4DB81DAF8BQ37373640-9EACF34D-5FAF-49BB-8290-90BC4ED4EC7EQ37394894-7ABEB319-13A9-4115-B609-EF826CBCC6CDQ37432375-2B2E02CD-604D-41CE-AF60-A5C0CDF67378Q37584993-CEF08657-FFB4-4A87-AE0A-FB1C4B248BBCQ37638935-FFE02B20-C415-40AC-A2A8-0CE8B4695A98Q37684642-09DA6AEE-47BE-4056-8B53-5B17F3712A15Q37827340-88AD4541-F18B-497C-9861-A64C495DCC26Q38006838-15EC3083-7E9B-4E8B-BD20-2722D5C62E4AQ38926178-9CE2701C-61CA-455B-866A-DC117AA3FB1DQ38990966-EFEDB6F8-5706-427B-B0EB-64A17C7A1E71Q39026766-5694D977-D567-447B-BAAF-65CF2FA0FA7EQ39682934-6DABEF27-91A4-4849-843C-71B86E1474D0Q41024459-54C38C18-941F-4EBF-9928-29BC58204DBDQ51205063-046E07BB-F483-48D7-9C18-BCDD8CA75CD4Q52649713-290689FD-944F-432F-9BF9-1AF5C594E174Q54541551-F11A612A-6DD2-44E9-B569-39ACA5373F3DQ55070097-66CB1BC0-056C-460F-B67E-067CD21BAE6B
P2860
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
EphA2 overexpression is associ ...... outcome in endometrial cancer.
@ast
EphA2 overexpression is associ ...... outcome in endometrial cancer.
@en
type
label
EphA2 overexpression is associ ...... outcome in endometrial cancer.
@ast
EphA2 overexpression is associ ...... outcome in endometrial cancer.
@en
prefLabel
EphA2 overexpression is associ ...... outcome in endometrial cancer.
@ast
EphA2 overexpression is associ ...... outcome in endometrial cancer.
@en
P2093
P2860
P356
P1433
P1476
EphA2 overexpression is associ ...... outcome in endometrial cancer.
@en
P2093
Anil K Sood
Aparna A Kamat
Creighton Edwards
Diana Urbauer
Donna Coffey
Elizabeth Nugent
Robert L Coleman
Russell Broaddus
William M Merritt
Yvonne G Lin
P2860
P304
P356
10.1002/CNCR.24335
P407
P577
2009-06-01T00:00:00Z